Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Impact Factor 13.965
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation Research

  • My alerts
  • Sign In
  • Join

  • Impact Factor 13.965
  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Integrative Physiology

Enhanced Cardiomyocyte DNA Synthesis During Myocardial Hypertrophy in Mice Expressing a Modified TSC2 Transgene

Kishore B. S. Pasumarthi, Hidehiro Nakajima, Hisako O. Nakajima, Shaoliang Jing, Loren J. Field
Download PDF
https://doi.org/10.1161/01.RES.86.10.1069
Circulation Research. 2000;86:1069-1077
Originally published May 26, 2000
Kishore B. S. Pasumarthi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hidehiro Nakajima
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hisako O. Nakajima
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaoliang Jing
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loren J. Field
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics

Jump to

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters
Loading

Abstract

Abstract—Tuberous sclerosis complex (TSC) is a rare genetic disorder characterized by the appearance of benign tumors in multiple organs, including the heart. Disease progression is accompanied by homozygous mutation at 1 of 2 loci (designated TSC1 or TSC2), leading to the suggestion that these genes function as tumor suppressors. In this study, we generated a series of TSC2 cDNAs in which one or more structural motifs were deleted, with the hope that expression of the modified gene product would override the growth-inhibitory activity of the endogenous TSC2 gene product. Several of the modified cDNAs enhanced growth rate, increased endocytosis, and promoted aberrant protein trafficking when expressed in NIH-3T3 cells, thereby mimicking phenotypes typical of TSC2-deficient cells. Surprisingly, targeted expression of the most potent TSC2 cDNA to the heart did not perturb cardiac development. However, the level of cardiomyocyte DNA synthesis in adult transgenic mice was elevated >35-fold during isoproterenol-induced hypertrophy compared with their nontransgenic siblings. These results suggest that alteration of TSC2 gene activity in combination with β-adrenergic stimulation can reactivate the cell cycle in a limited number of terminally differentiated adult cardiomyocytes.

  • tumor suppressor
  • cardiac regeneration

Tuberous sclerosis complex (TSC) is characterized by the appearance of nonmalignant tumors in a wide spectrum of organs, including the brain, kidney, lung, skin, and heart. The familial form of the disease exhibits an autosomal dominant pattern of inheritance, and 2 disease-causing loci (designated TSC1 and TSC2) have been identified. The TSC1 gene, which encodes a 130-kD protein called hamartin, is located at chromosome 9q34.1 The TSC2 gene, which encodes a 198-kD protein called tuberin, is located at chromosome 16p13.3.2 Molecular analyses have demonstrated that tumor formation in TSC patients is frequently associated with loss of heterozygosity at either locus,3 4 confirming earlier predictions based on genetic analyses that the TSC genes function as tumor suppressors. This view is further supported by analyses of Eker rats, which carry a mutation at the TSC2 locus.5 6 Rats homozygous for the TSC2 mutation die in utero at embryonic day 13.5, whereas rats heterozygous for the TSC2 mutation are viable but highly prone to renal carcinoma. Tumor progression in the heterozygous Eker rats is accompanied by loss of heterozygosity at the TSC2 locus, and expression of a transgene encoding a wild-type TSC2 cDNA blocks renal carcinoma in this model.7

Primary myocardial tumors in the general population are extremely rare.8 In contrast, >50% of TSC patients exhibit primary myocardial tumors.9 These results suggest that the TSC gene products play an important role in the regulation of the cardiomyocyte cell cycle. This view is supported by analysis of embryonic day 12.5 fetuses derived from intercrosses of heterozygous Eker rats.10 Spontaneously contractile cardiomyocytes were observed after multiple passages of whole-embryo cultures prepared from fetuses homozygous for the mutant TSC2 allele but not from cultures prepared from heterozygous or wild-type fetuses. Immune cytological and electron microscopic analyses confirmed that the contractile cells in the homozygous mutant cultures were cardiomyocytes. Tritiated thymidine incorporation analyses indicated that these cells exhibited sustained DNA synthesis after as many as 8 passages. Although disruption of the TSC2 gene resulted in embryo death in mice, histological analyses suggested the presence of enhanced ventricular myocardial proliferation in the homozygous mutant fetuses.11 Thus, the TSC2 gene product is important for cardiomyocyte terminal differentiation.

Molecular analyses have identified several structural motifs that appear to be important for tuberin activity. For example, a small 38-amino-acid motif near the C-terminus of tuberin exhibits homology to the GTPase-activating protein rap1GAP,2 12 a protein that negatively regulates rap1. Rap1, a member of the ras superfamily, was originally isolated by its ability to diminish the transforming activity of the Ki-ras mutant.13 The observation that tuberin stimulated the GTPase activity of rap1a suggested that this motif is functionally active,14 a view supported indirectly by the colocalization of these two proteins in the Golgi apparatus.15 Other studies identified a 59-amino-acid motif located at the C-terminus of tuberin that binds to rabaptin-5.16 Rabaptin-5 is a direct effector of the small GTPase Rab5, a rate-limiting component of the endocytotic membrane docking apparatus.17 Tuberin possesses potent Rab5 GAP activity,16 leading these authors to propose that rabaptin-5 functions as an adaptor protein to recruit Rab5 for tuberin-mediated GAP activity. In support of this, abnormally high levels of endocytosis were observed in embryonic fibroblasts lacking tuberin. More recently, tuberin amino acid residues 346 to 371 were shown to be sufficient for binding to hamartin, the product of the TSC1 gene.18 Finally, an alternatively spliced region encoding a leucine zipper located at the N-terminus of the protein has also been identified.19

In this study, we generated modified TSC2 cDNAs in which one or more of these structural motifs were altered. The modified cDNAs were then screened for their ability to promote growth in NIH-3T3 cells, which express relatively high levels of the endogenous tuberin gene product. Cells expressing the modified cDNAs exhibited phenotypes typical of TSC2-deficient cells, including enhanced growth rates, increased endocytosis, and aberrant p27 trafficking. The cDNA exhibiting the greatest growth-promoting activity in cell culture was tested for its ability to alter cardiomyocyte cell cycle regulation in vivo. Although cardiac development in transgenic mice expressing the cDNA under the control of the α-cardiac myosin heavy chain (MHC) promoter appeared normal, the level of cardiomyocyte DNA synthesis during isoproterenol-induced hypertrophy was ≈35-fold greater than that observed in nontransgenic siblings. These results are discussed within the context of promoting regenerative growth in the adult myocardium.

Materials and Methods

Recombinant DNA Protocols

Isolation and characterization of the wild-type murine tuberin cDNA was described previously.19 All recombinant DNA manipulations used standard methodologies,20 and construct fidelity was confirmed by diagnostic DNA sequencing. All animal experimentation was in accordance with institutional and federal guidelines.

Cell Culture Experiments

For colony growth assays, TSC2 cDNAs were subcloned into pRcCMV and transfected into NIH-3T3 cells.20 Cells were selected in G418 for 13 days (0.3 mg/mL), and the dishes were then stained with 0.1% gentian violet. Stable cell lines were isolated by long-term selection with G418. To monitor the effect of transgene expression on growth, stable cell lines were plated in triplicate at a density of 104 cells/100-mm dish and cultured for 2, 4, 6, and 8 days. Total cell number was determined at each time point with a hemocytometer. For tumorigenesis analysis in SCID mice, 106 cells of each line were injected into SCID/NOD mice. Tumor growth was scored as positive when the tumor mass reached a 2.5-cm diameter.

Western Blot Analyses

Cells or hearts were homogenized directly in NP40 buffer and processed as described previously.21 22 The TSC2 antibody used in this study was C-20 (Santa Cruz Biochemicals). Signal was visualized by the enzyme-linked chemiluminescence method according to the manufacturer’s protocol (Amersham).

Endocytosis Assay

Fluid-phase endocytosis was quantified with a horseradish peroxidase (HRP) uptake assay.23 HRP uptake was determined by measuring the absorbency values at 455 nm and normalized to the protein content in the sample.

p27 Immune Reactivity

Cells plated in chamber slides were serum-synchronized, fixed in ice-cold acetone and methanol (1:1), and processed for anti-p27 immune cytology (antibody sc-528, Santa Cruz Biochemicals) at a 1:100 dilution. p27 immune reactivity signal was visualized with a Vectastain ABC kit from Vector Laboratories.

Generation of the MHCΔRL Transgenic Mice

The MHCΔRL transgene was constructed by use of the transcriptional regulatory sequences of the mouse MHC gene24 and the TSC2 ΔRL cDNA. The SV40 early-region transcription terminator/polyadenylation site (nucleotide residues 2586 to 2452)25 was inserted downstream from the ΔRL cDNA insert. Transgene insert DNA was microinjected into zygotes by standard methodologies.26 Transgenic animals were identified by diagnostic polymerase chain reaction amplification as described.27

Cardiomyocyte DNA Synthesis Assays

Cardiomyocyte DNA synthesis was monitored with a thymidine incorporation assay and an MHC-nLAC reporter transgenic strain as described.28 29 Mice received a single injection of [3H]thymidine [200 μCi IP at 28 Ci/(mmol/L), Amersham] and were euthanized 4 hours later. Standard methods were used for cryosectioning.30 Cardiomyocyte DNA synthesis was scored by the colocalization of β-galactosidase (β-gal) activity (dark blue staining when visualized under bright-field illumination) and silver grains. For anti-tuberin immune cytology, heart sections were reacted with anti-tuberin antibody C-20, and signal was visualized with a Vectastain ABC kit from Vector Laboratories.

Myocardial Hypertrophy Model

Myocardial hypertrophy was induced by isoproterenol infusion with Alzet minipumps in adult mice as described previously.31

An expanded Materials and Methods section is available online at http://www.circresaha.org.

Results

Colony Growth Screen for TSC2 Modifications With Growth-Promoting Activity

Previous analyses have identified several conserved motifs in human,2 rat,32 and mouse19 tuberin and to a lesser degree in puffer fish33 and Drosophila tuberin.34 These include a leucine zipper near the N-terminus of the molecule, as well as a rap1GAP homology motif and a rabaptin-5 binding motif near the C-terminus (Figure 1A⇓). The high level of conservation suggests that these motifs may be important for tuberin tumor suppressor activity, a prediction that has been partially born out by functional studies (see Introduction). A series of TSC2 cDNA expression constructs in which the rap1GAP, leucine zipper, or rabaptin-5 motifs were deleted individually or in combination were generated (see Figure 1A⇓) and tested for their ability to promote growth when expressed in cells with high levels of the endogenous TSC2 gene product. The expression constructs used the cytomegalovirus (CMV) promoter and also carried a neor expression cassette to facilitate selection of transfected cells.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

A, Schematic of the modified TSC2 cDNAs used in this study. The positions of the leucine zipper (L), rap1GAP (G), and rabaptin-5 (R) motifs are indicated. For the ΔG construct, amino acid residues 1617 through 1655 were deleted. For the ΔL construct, amino acid residues 81 through 102 were deleted. For the ΔR construct, a splice variant in which amino acid residues 1679 through 1742 were substituted was used. WT is the wild-type TSC2 cDNA. B, Colony growth assay of NIH-3T3 cells transfected with the various TSC2 expression constructs. Transfected cells were selected for 13 days in G418, and the dishes were fixed and stained with gentian violet. Transfection efficiencies were calculated by monitoring expression of a cotransfected CMV–β-gal reporter gene at 48 hours after transfection. β-gal activities (relative luminescence/mg protein, ×105) were: CMV-null, 1.7±0.12; CMVΔR, 1.7±0.12; CMVΔG, 1.7±0.06; CMVΔL, 1.7±0.06; CMVΔRL, 1.7±0.06; CMVΔRG, 1.6±0.15; CMVΔRGL, 1.8±0.15; and CMV-WT, 1.7±0.66. There was no significant difference between groups by Kruskal-Wallis nonparametric ANOVA test.

A colony growth assay was used to monitor the impact of the modifications on cell growth. NIH-3T3 cells were transfected with the various constructs, and the resulting colonies were visualized by gentian violet staining after 13 days of G418 selection (Figure 1B⇑). Small colonies were observed in dishes transfected with expression vector lacking a cDNA insert (CMV-null construct), indicative of the rate of proliferation under the conditions used. Smaller and fewer colonies were observed in dishes transfected with a full-length wild-type TSC2 construct (CMV-WT), consistent with the previously described growth-suppressing activity of this molecule. Colonies in dishes transfected with constructs in which the rap1GAP (CMVΔG) or leucine zipper (CMVΔL) motifs were disrupted grew to the same extent as those transfected with the CMV-null construct. Colonies in dishes transfected with constructs in which the rabaptin-5 motif was disrupted (CMVΔR) exhibited a modest but reproducible increase in size relative to the CMV-null control.

Expression vectors encoding tuberin molecules with combinatorial mutations were then generated to determine whether synergistic effects could be obtained. Markedly increased colony growth was observed in dishes transfected with constructs encoding tuberin molecules lacking the rabaptin-5 and rap1GAP motifs (CMVΔRG) or the rabaptin-5 and leucine zipper motifs (CMVΔRL; see Figure 1B⇑). Paradoxically, growth inhibition (similar to that obtained with the wild-type tuberin construct) was observed in cells transfected with a construct in which all 3 motifs were disrupted (CMVΔRGL). These results were reproduced in 4 independent experiments using a minimum of 3 independent DNA preparations; moreover, no significant difference in transfection efficiency was observed between the different constructs.

Modified TSC2 cDNAs Promote Cell Growth In Vitro and In Vivo

Stable NIH-3T3 cell lines harboring the growth-promoting constructs were generated to determine the consequences of long-term transgene expression. Cell lines with the CMV-null and CMV-WT constructs were generated as controls. Western blot analyses indicated that each construct expressed similar amounts of recombinant protein (Figure 2A⇓: data from representative cell lines are shown; the level of recombinant protein expression was ≈2- to 3-fold greater than that of the endogenous tuberin gene product). Cells from each group were plated in triplicate at a density of 104 cells/100-mm dish and cultured for 2, 4, 6, and 8 days. The cultures were then trypsinized and the cell numbers determined (Figure 2B⇓). In agreement with the colony growth assay, cells expressing the CMVΔRL and CMVΔRG constructs exhibited the highest rate of proliferation. Similar results were obtained when 6 independent cell lines for each construct were analyzed (not shown).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

A, Western blot analysis of tuberin expression in NIH-3T3 cells transfected with various control and TSC2 expression constructs. The molecular weight shift resulting from various modifications was of insufficient magnitude to resolve on a 7.5% polyacrylamide gel used in this study. B, Growth curves for representative cell lines stably transfected with various control and TSC2 expression constructs. Each time point was analyzed in triplicate, and the error bars indicate the SEM. Growth rate values at days 6 and 8 were significantly different from the CMV-null controls (CMVΔRG, P<0.005; CMVΔRL, P<0.001; ANOVA with Bonferroni multiple comparison test). C, Kaplan-Meier plot of tumor-free mice after injection of 106 cells expressing control or TSC2 constructs. D, Western blot analysis of tuberin expression in tumors recovered from transplanted SCID mice. Note that sustained tuberin expression was present.

A SCID mouse tumor assay was used to determine whether the enhanced growth observed with the CMVΔRL and CMVΔRG constructs in vitro persisted in vivo. Cells expressing these constructs were injected into NOD/SCID mice (106 cells/mouse; 8 mice per group), and the animals were sequestered and monitored for tumor formation. The CMV-null and CMV-WT cell lines were used as controls. Tumor formation was accelerated in cells expressing the CMVΔRL and CMVΔRG constructs compared with the CMV-null construct, confirming that the growth enhancement of these modified tuberin cDNAs persisted in vivo (Figure 2C⇑). Western blot analyses revealed sustained tuberin expression in tumor material recovered from the mice (Figure 2D⇑). Interestingly, no tumors were detected in mice injected with cells expressing the CMV-WT construct, which provides compelling proof of the growth-suppressing activity of wild-type tuberin (the experiment was terminated after 125 days). To determine whether this tumor suppressor activity was associated with apoptosis, CMV-null and CMV-WT cultures were processed for in situ end-labeling (ISEL) reactivity, which provides a sensitive assay for DNA fragmentation.35 Many cells in the CMV-WT cultures had markedly condensed chromatin (visualized via Hoechst staining, blue signal), which was also positive for ISEL reactivity (green signal, see Figure 3A⇓). Further inspection under phase-contrast illumination confirmed that the cells were dying (Figure 3A⇓). Quantitative analysis of the cultures revealed that cells expressing the CMV-WT construct were highly prone to apoptosis (Figure 3B⇓).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

A, Cultured CMV-WT cells were stained with Hoechst to visualize chromatin (blue signal), processed for ISEL reactivity to identify nuclei with fragmented DNA (green signal), and visualized under phase contrast for morphological analysis. Arrow indicates a cell with markedly condensed chromatin and fragmented DNA that appears to be undergoing apoptosis. B, Quantitative assessment of ISEL-positive nuclei in CMV-null and CMV-WT cultures grown in the presence of 10% or 0.1% serum. There was a significantly higher incidence of ISEL-positive nuclei in the CMV-WT cultures than in the CMV-null cultures (P<0.005, unpaired t test). Similar rates of apoptosis were seen in unselected NIH-3T3 cells and CMV-null cells.

Increased Endocytosis and Aberrant Protein Trafficking in Cells Expressing Modified TSC2 cDNAs

Recent studies have suggested that loss of tuberin activity results in increased endocytosis16 and aberrant trafficking of negative cell cycle–regulatory proteins.34 36 Endocytosis was measured in the CMV-null, CMVΔRG, and CMVΔRL cell lines with an HRP uptake assay.23 A 2- to 2.5-fold increase in endocytosis rates was observed in the CMVΔRL and CMVΔRG cell lines compared with the CMV-null control (Figure 4A⇓). The subcellular localization of p27, a negative regulator of the S-phase cyclin-dependent kinases, was also monitored. Prominent nuclear p27 immune reactivity was seen in the CMV-null control cells (Figure 4B⇓). In contrast, only weak and diffuse cytoplasmic p27 immune reactivity was observed in the CMVΔRL cells (Figure 4C⇓). Cytoplasmic p27 immune reactivity was also observed in the CMVΔRG cells (data not shown).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

A, HRP endocytosis assay for CMV-null, CMVΔRG, and CMVΔRL cell lines. Results are normalized relative to the value for the CMV-null cells. Error bars indicate SEM. Each cell line was analyzed in triplicate. Endocytosis values were significantly different from the CMV-null controls (CMVΔRG, P<0.0005; CMVΔRL, P<0.0001; unpaired t test). B, Photomicrograph of a CMV-null cell processed for p27 immune reactivity (HRP-conjugated secondary antibody, black signal). Prominent nuclear p27 immune reactivity is seen. Of the cells expressing the CMV-null transgene, 97.1±0.52% exhibited nuclear p27 immune reactivity (n=500). C, Photomicrograph of a CMVΔRL cell processed for p27 immune reactivity (HRP-conjugated secondary antibody, black signal). Diffuse cytoplasmic p27 immune reactivity is seen; no signal is apparent in the nucleus. Only 4.2±0.34% of the cells expressing the CMVΔRL transgene exhibited nuclear p27 immune reactivity (n=500); the remainder of the cells had predominantly cytoplasmic immune reactivity.

Cardiac Development Is Normal in Transgenic Mice Expressing the TSC2ΔRL cDNA in the Heart

We next determined whether targeted expression of a modified TSC2 cDNA would alter cardiac development in transgenic mice. The TSC2ΔRL cDNA was tested, because this modification had the greatest effect on cell growth in NIH-3T3 cells. A transgene comprising the mouse α-cardiac MHC promoter and the ΔRL tuberin cDNA was produced (Figure 5A⇓). The resulting transgene (designated MHCΔRL) was microinjected into 1-cell embryos to produce transgenic animals. Seven of 29 mice born from the microinjected embryos were transgenic. These mice gave rise to 3 independent lineages, and transgene expression was stratified via Western blot analysis. MHCΔRL line 1 expressed high levels of the transgene (Figure 5B⇓) and was selected for subsequent analysis. Endocytosis was examined in primary cardiomyocyte cultures prepared from control and MHCΔRL mice. Endocytosis was increased ≈2.5-fold in the transgenic hearts (Figure 5C⇓), consistent with the biological activity observed for the TSC2ΔRL cDNAs in cultured cells.

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

A, Schematic of the MHCΔRL transgene. The MHC promoter consisted of 4.5 kb of 5′ flanking sequence and 1 kb of the gene including exon 1, exon 2, and a portion of exon 3. SV40 refers to the SV40 early region transcription terminator and polyadenylation sequences. B, Western blot analysis demonstrating recombinant tuberin expression in the MHCΔRL transgenic heart. (−) indicates the level of tuberin expression in nontransgenic animals. C, HRP endocytosis assay of primary heart cultures prepared from nontransgenic and MHCΔRL transgenic hearts in the absence or presence of isoproterenol. Results are normalized relative to the value for the nontransgenic hearts in the absence of isoproterenol treatment. Error bars indicate SEM. Endocytosis values for the transgenic hearts were significantly different from the nontransgenic controls (MHCΔRL, P<0.0001; unpaired t test).

To monitor the consequences of transgene expression on cardiomyocyte DNA synthesis, the MHCΔRL mice were crossed with MHC-nLAC transgenic mice,28 29 which express a nuclear localized β-gal reporter under the regulation of the MHC promoter. Reporter gene activity permits rapid and unambiguous identification of cardiomyocyte nuclei in histological sections by simple X-Gal staining (cardiomyocyte nuclei appear dark blue as a result of the nuclear β-gal activity). Progeny inheriting both the MHC-nLAC and MHCΔRL transgenes were used as experimental animals, and those inheriting only the MHC-nLAC transgene were used as controls. There was no evidence of altered cardiac growth (Table⇓; 11-week-old mice were examined). Histochemical analyses did not detect any overt consequences of transgene expression.

View this table:
  • View inline
  • View popup
Table 1.

Cardiac Attributes in MHCΔRL Transgenic Mice

To monitor the effect of transgene expression on adult cardiomyocyte DNA synthesis, mice received a single injection of tritiated thymidine, and the hearts were then harvested and cryosectioned. The resulting sections were stained with X-Gal and then processed for autoradiography. Cardiomyocyte DNA synthesis was scored by colocalization of β-gal activity and silver grains in autoradiograms of histological sections. Approximately 100 000 cardiomyocyte nuclei were counted for the experimental and control animals (n=5 animals per group). No cardiomyocyte DNA synthesis was observed in any of the animals (see Table⇑). Analyses of older MHCΔRL transgenic mice revealed no evidence of myocardial tumorigenesis (18 months old) or cardiomyocyte DNA synthesis (12 months old, 60 000 nuclei screened).

Myocardial Hypertrophy Stimulates Cardiomyocyte DNA Synthesis in MHCΔRL Mice

Cardiomyocyte DNA synthesis was also monitored during isoproterenol-induced cardiac hypertrophy. After 7 days of isoproterenol infusion, a similar hypertrophic response was observed in the control MHC-nLAC and experimental MHC-nLAC/MHCΔRL animals (36±4.3% increase in HW/TL for control mice, 40±4.3% increase in HW/TL for experimental mice, see Table⇑). In addition, a similar induction in ventricular atrial natriuretic factor mRNA expression was observed for the isoproterenol-treated control and experimental animals (not shown). The tritiated thymidine incorporation assay failed to detect any cardiomyocyte DNA synthesis in the MHC-nLAC mice after isoproterenol-induced hypertrophy (see Table⇑; ≈100 000 nuclei were counted). In contrast, DNA synthesis was reactivated in the ventricular myocardium of the MHCΔRL transgenic mice during isoproterenol-induced hypertrophy (see Table⇑). Examples of cardiomyocytes synthesizing DNA (as evidenced by colocalization of silver grains and nuclear β-gal activity) are shown in Figure 6A⇓ and 6B⇓. An overall cardiomyocyte tritiated thymidine labeling index of 0.018% was observed in the ventricles of MHCΔRL transgenic mice after 7 days of isoproterenol infusion. Immune histological analyses confirmed that the cells synthesizing DNA were expressing the MHCΔRL transgene (Figure 6C⇓, arrow). Moreover, the level of transgene expression appeared to be similar to that in cardiomyocytes not synthesizing DNA (Figure 6C⇓, arrowheads). Isoproterenol treatment had no effect on endocytosis in the transgenic hearts (Figure 5C⇑), suggesting that β-adrenergic stimulation did not directly alter transgene activity. Finally, infusion of phenylephrine failed to reactivate cardiomyocyte DNA synthesis in the MHCΔRL transgenic mice, despite a marked hypertrophic response (52.0% increase in HW/BW ratio, 60 000 nuclei screened). This finding suggests that reactivation of cardiomyocyte DNA synthesis in MHCΔRL mice is dependent on β-adrenergic stimulation, rather than a simple response to hypertrophic myocardial growth.

Figure 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6.

A and B, Examples of cardiomyocyte DNA synthesis in sections prepared from MHC-nLAC/MHCΔRL transgenic animals with cardiac hypertrophy. After 7 days of isoproterenol infusion, the mice received a single injection of tritiated thymidine, and the hearts were harvested, sectioned, and processed for X-Gal staining and autoradiography. C, Analysis of tuberin immune reactivity and DNA synthesis in MHCΔRL cardiomyocytes. Tuberin immune reactivity was detected via HRP assay (reddish brown signal); cardiomyocyte nuclei were visualized by X-Gal staining. Similar levels of transgene expression were seen in cardiomyocytes synthesizing DNA (arrow) and cardiomyocytes that were not synthesizing DNA (arrowheads). The photographic emulsion used for the autoradiograph in C has finer grain, hence the difference in silver grain size compared with A and B.

Discussion

The experiments described above were based on the premise that expression of TSC2 cDNAs in which one or more structural motifs were altered might antagonize the activity of the endogenous gene product and thereby mimic TSC2 deficiency. We selected 3 structural motifs for which there was either direct experimental evidence attesting to functional importance (the rap1GAP and rabaptin-5 binding motifs), or alternatively, evidence for splice variants that directly altered or deleted the motif (the leucine zipper). We have not yet tested the consequence of deleting the hamartin-binding domain, which has only recently been identified.18

Cells Expressing the ΔRG and ΔRL cDNAs Mimic TSC2-Deficient Cells

Loss of tuberin activity is associated with enhanced rates of proliferation.37 Similarly, enhanced proliferation was observed in the CMVΔRG and CMVΔRL cell lines. A 2-fold increase in endocytosis was reported in homozygous mutant Eker rat embryonic fibroblasts compared with wild-type fibroblasts.16 A similar increase in endocytosis was observed in CMVΔRL and CMVΔRG cells. Finally, aberrant subcellular localization of the cyclin-dependent kinase inhibitor p27 was observed in tuberin-deficient cells36 as well as in the CMVΔRG and CMVΔRL cells. Thus, cells expressing the ΔRG or ΔRL cDNAs share multiple phenotypic attributes with tuberin-deficient cells.

Given that tuberin clearly interacts with multiple proteins (including hamartin, rap1a, and rabaptin-5), it is relatively easy to envision how the modified cDNAs could interfere with the activity of the endogenous gene product. For example, tuberin encoded by the ΔRL cDNA would lack the ability to bind rabaptin-5 and interact with other leucine zipper proteins but would nonetheless retain the capacity to interact with rap1 and potentially other G proteins. Expression of the ΔRL protein could effectively block the activity of the endogenous tuberin (and thereby mimic a loss of function mutation) by a simple titration mechanism. If a generalized scheme in which a disruption of protein/protein interactions underlies the observed cell cycle effects is correct, we would anticipate that some TSC2 mutations in TSC patients could act in a dominant negative manner (provided that the mutated protein was expressed at a high enough level to compete with the wild-type gene product). In that regard, it is of interest to note that a mutation encompassing an L717R substitution in tuberin resulted in the formation of multiple lung cysts in the absence of loss of heterozygosity, consistent with dominant negative activity.38

Cardiac Development Is Normal in MHCΔRL Mice

Both clinical and experimental observations support the notion that tuberin activity is important for normal cardiomyocyte terminal differentiation. Given the effects of TSC2ΔRL cDNA expression in cell culture experiments, it was surprising that cardiac development was normal in the MHCΔRL mice. No apparent morbidity or mortality was associated with myocardial transgene expression, nor was there evidence for either abnormal cardiac hypertrophy or sustained cardiomyocyte DNA synthesis in unperturbed adult transgenic mice. Additional studies failed to detect any differences in cardiomyocyte nucleation or gross histological appearance in fetal and adult transgenic mice compared with their nontransgenic sibs (K.B.S.P. and L.J.F., unpublished observations). It would thus appear that expression of the TSC2ΔRL cDNA did not perturb the normal process of cardiomyocyte terminal differentiation. This is in contrast to the situation in homozygous mutant Eker fetuses10 and in TSC2 patients,9 in whom there is clear evidence for increased cardiomyocyte proliferation in the absence of tuberin expression.

This observation suggests that expression of the TSC2ΔRL cDNA in cardiomyocytes is not functionally equivalent to disruption of the tuberin gene. It is possible that the relative level of transgene expression was insufficient to completely antagonize the activity of the endogenous tuberin. It is nonetheless clear that the TSC2ΔRL cDNA is biologically active, as evidenced by markedly increased cardiomyocyte endocytosis in the transgenic animals. The absence of a developmental phenotype might also be attributable to the timing of transgene expression. In the case of the Eker rat studies, the homozygous mutant embryos never express tuberin. Consequently, tuberin deficiency preceded cardiomyogenic differentiation in that model. In contrast, the TSC2ÄRL cDNA was under regulation of the MHC promoter, and as such, transgene expression was not induced until after cardiomyogenic differentiation in the atria and not until birth in the ventricles.24 If a developmental cardioproliferative phenotype requires compromised tuberin activity during cardiomyogenic differentiation or early cardiac development, the transgenic model could not recapitulate this phenotype. It is difficult to directly compare the transgenic mouse model with clinical observations, because it is not clear when in cardiac development myocardial cells (or their precursors) become tuberin-deficient in TSC patients. Finally, as with all transgenic mouse models, we cannot rule out the possibility that sustained transgene expression has altered the normal developmental program, thereby making the myocardium less sensitive to targeted expression of the TSC2ΔRL cDNA.

Potential Mechanism for the Reactivation of Cardiomyocyte DNA Synthesis After β-Adrenergic Stimulation in MHCΔRL Mice

Given that cardiomyocyte terminal differentiation was normal in the MHCΔRL mice, it was surprising that isoproterenol-induced hypertrophy reactivated cardiomyocyte DNA synthesis in adult animals. A cardiomyocyte DNA synthesis rate of 0.018% was observed in the MHCΔRL mice after a single injection of isotope. Although no DNA synthesis was detected in the control MHC-nLAC hearts in the present study, previous experiments have established a maximum cardiomyocyte DNA synthesis rate of ≈0.0005% in both unperturbed adult mice28 and in isoproterenol-treated animals.31 It should be noted that there is some discrepancy in the literature regarding the rates of cardiomyocyte DNA synthesis in normal and injured adult hearts (reviewed in References 39 and 40 ). Regardless of the differences observed in different species and with different models of cardiac injury, the salient observation in the present study is that transgene expression does not effect cardiomyocyte DNA synthesis in normal adult hearts but results in a 35-fold increase in cardiomyocyte DNA synthesis during hypertrophic myocardial growth.

The persistent cytoplasmic sequestration of p27 in mutant Eker embryonic fibroblasts36 and M-phase cyclins in TSC2-deficient Drosophila embryos34 suggest that anomalous protein trafficking might underlie the altered cell cycle regulation observed in tuberin-deficient cells. Expression of the TSC2ΔRL cDNA also perturbed p27 subcellular localization in transfected NIH-3T3 cells. Reactivation of cardiomyocyte DNA synthesis during cardiac hypertrophy in the MHCΔRL transgenic mice may result from a similar mechanism. In vitro, hypertrophic stimulation of cultured neonatal cardiomyocytes (for example, angiotensin II treatment or mechanical stretch) is associated with a transient increase in a number of positive cell cycle–regulatory proteins, including immediate early genes, proto-oncogenes, and such G1/S regulatory proteins as D-type cyclins, CDK4, and hyperphosphorylated RB.41 42 Increased expression of many of these same gene products has been documented during cardiac hypertrophy in vivo.43 Although induction of these growth-promoting gene products during hypertrophy is insufficient to reactivate cardiomyocyte DNA synthesis in nontransgenic hearts (see Table⇑),28 induction in a genetic background in which negative growth-regulatory pathways are compromised could easily result in reactivation of cardiomyocyte DNA synthesis. Importantly, the activities of many of these gene products are directly antagonized by p27 and other CDK inhibitors, which appear to be preferentially affected by anomalous protein trafficking in TSC2-deficient fibroblasts.

Expression of the MHCΔRL transgene resulted in a 35-fold increase in the level of cardiomyocyte DNA synthesis during isoproterenol-induced hypertrophy compared with the nontransgenic animals. However, the absolute number of cardiomyocytes synthesizing DNA was low. Regional variability in the level of expression of CDK inhibitors throughout the myocardium,44 coupled to a global increase in cyclin and CDK expression observed in some instances during myocardial hypertrophy,45 may explain why only a small fraction of the cardiomyocytes expressing the MHCΔRL transgene reactivate DNA synthesis. Importantly, isoproterenol had no effect on endocytosis in the transgenic cardiomyocytes, suggesting that β-adrenergic stimulation did not directly alter transgene activity. Although several studies46 47 48 49 support a potential role for p27 in the cardiomyocyte DNA synthesis seen in hypertrophic MHCΔRL hearts, preliminary efforts have failed to detect cytoplasmic sequestration of this protein in the transgenic hearts (K.B.S.P., unpublished observations). Thus, if aberrant protein trafficking does underlie the phenotype in the MHCΔRL hearts, it most likely results from dysregulation of another protein(s). Given the pivotal role of Rab5 in regulating endocytosis and vesicle membrane docking,17 it is likely that intracellular protein trafficking is compromised to some degree in the MHCΔRL hearts. At present, it is not clear whether those cardiomyocytes synthesizing DNA ultimately undergo karyokinesis and/or cytokinesis. Finally, it appears that the rap1GAP activity encoded by TSC2 is not important for adult cardiomyocyte cell cycle reactivation, because no DNA synthesis was detected in normal or hypertrophic hearts from mice expressing an MHCΔRG transgene (K.B.S.P. and L.J.F., unpublished observations).

Implications for Regenerative Myocardial Growth

Although a limited number of cardiomyocytes in the MHCΔRL mice retained the capacity to reenter the cell cycle in response to specific stimuli, the absence of DNA synthesis in unperturbed transgenic hearts suggests that developmental cell cycle withdrawal proceeds normally in these animals. This is in contrast to other transgenic models (as exemplified by mice expressing cyclin D1 in the myocardium),50 in which adult cardiomyocyte DNA synthesis appeared to result from a failure of the terminal differentiation process. This distinction is extremely important if the gene (or pathway) under study is to be exploited for therapeutic intervention in diseased hearts. Many forms of cardiovascular disease are accompanied by cardiomyocyte loss, and it is generally accepted that the regenerative capacity of the adult myocardium is limited.39 40 The ability to reactivate the cell cycle in the adult heart, thereby effecting regenerative growth, could thus be of considerable therapeutic utility. Targeted expression of the ΔRL tuberin cDNA, in conjunction with isoproterenol stimulation, appears to have reactivated the cell cycle in a limited number of adult cardiomyocytes. Identification of the pathway(s) activated in the responsive cells or alternatively, synergistic interaction with other regulatory pathways might provide a means to increase cell cycle reactivation to a point sufficient for regenerative cardiomyocyte growth.

Acknowledgments

This study was supported by the NHLBI and a grant from Bristol-Myers Squibb (Dr Field). Dr Pasumarthi was supported by a postdoctoral fellowship from the American Heart Association, Indiana Affiliate. We thank D. Field for excellent technical assistance and M. Soonpaa, S.-C. Tsai, and Brett Zani for comments on the manuscript.

  • Received November 18, 1999.
  • Accepted March 30, 2000.
  • © 2000 American Heart Association, Inc.

References

  1. ↵
    van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, Lindhout D, van den Ouweland A, Halley D, Young J, Burley M, Jeremiah S, Woodward K, Nahmias J, Fox M, Ekong R, Osborne J, Wolfe J, Povey S, Snell RG, Cheadle JP, Jones AC, Tachataki M, Ravine D, Kwiatkowski DJ, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277:805–808.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    The European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75:1305–1315.
    OpenUrlCrossRefPubMed
  3. ↵
    Green AJ, Johnson PH, Yates JR. The tuberous sclerosis gene on chromosome 9q34 acts as a growth suppressor. Hum Mol Genet. 1994;3:1833–1834.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Green AJ, Smith M, Yates JR. Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat Genet. 1994;6:193–196.
    OpenUrlCrossRefPubMed
  5. ↵
    Yeung RS, Xiao GH, Jin F, Lee WC, Testa JR, Knudson AG. Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc Natl Acad Sci U S A. 1994;91:11413–11416.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Kobayashi T, Hirayama Y, Kobayashi E, Kubo Y, Hino O. A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat Genet. 1995;9:70–74.
    OpenUrlCrossRefPubMed
  7. ↵
    Kobayashi T, Mitani H, Takahashi R, Hirabayashi M, Ueda M, Tamura H, Hino O. Transgenic rescue from embryonic lethality and renal carcinogenesis in the Eker rat model by introduction of a wild-type Tsc2 gene. Proc Natl Acad Sci U S A. 1997;94:3990–3993.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Braunwald E. Heart Disease. Philadelphia, Pa: WB Saunders; 1992.
  9. ↵
    Watson GH. Cardiac rhabdomyomas in tuberous sclerosis. Ann N Y Acad Sci. 1991;615:50–57.
    OpenUrlPubMed
  10. ↵
    Pajak L, Jin F, Xiao GH, Soonpaa MH, Field LJ, Yeung RS. Sustained cardiomyocyte DNA synthesis in whole embryo cultures lacking the TSC2 gene product. Am J Physiol. 1997;273:H1619–H1627.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Kobayashi T, Minowa O, Kuno J, Mitani H, Hino O, Noda T. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res. 1999;59:1206–1211.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Maheshwar MM, Cheadle JP, Jones AC, Myring J, Fryer AE, Harris PC, Sampson JR. The GAP-related domain of tuberin, the product of the TSC2 gene, is a target for missense mutations in tuberous sclerosis. Hum Mol Genet. 1997;6:1991–1996.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Kitayama H, Sugimoto Y, Matsuzaki T, Ikawa Y, Noda M. A ras-related gene with transformation suppressor activity. Cell. 1989;56:77–84.
    OpenUrlCrossRefPubMed
  14. ↵
    Wienecke R, Konig A, DeClue JE. Identification of tuberin, the tuberous sclerosis-2 product: tuberin possesses specific Rap1GAP activity. J Biol Chem. 1995;270:16409–16414.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Wienecke R, Maize JC Jr, Shoarinejad F, Vass WC, Reed J, Bonifacino JS, Resau JH, de Gunzburg J, Yeung RS, DeClue JE. Co-localization of the TSC2 product tuberin with its target Rap1 in the Golgi apparatus. Oncogene. 1996;13:913–923.
    OpenUrlPubMed
  16. ↵
    Xiao GH, Shoarinejad F, Jin F, Golemis EA, Yeung RS. The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis. J Biol Chem. 1997;272:6097–6100.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Stenmark H, Vitale G, Ullrich O, Zerial M. Rabaptin-5 is a direct effector of the small GTPase Rab5 in endocytic membrane fusion. Cell. 1995;83:423–432.
    OpenUrlCrossRefPubMed
  18. ↵
    van Slegtenhorst M, Nellist M, Nagelkerken B, Cheadle J, Snell R, van den Ouweland A, Reuser A, Sampson J, Halley D, van der Sluijs P. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Human Mol Genet. 1998;7:1053–1057.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Kim KK, Pajak L, Wang H, Field LJ. Cloning, developmental expression, and evidence for alternative splicing of the murine tuberous sclerosis (TSC2) gene product. Cell Mol Biol Res. 1995;41:515–526.
    OpenUrlPubMed
  20. ↵
    Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
  21. ↵
    Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680–685.
    OpenUrlCrossRefPubMed
  22. ↵
    Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979;76:4350–4354.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Stenmark H, Bucci C, Zerial M. Expression of Rab GTPases using recombinant vaccinia viruses. Methods Enzymol. 1995;257:155–164.
    OpenUrlCrossRefPubMed
  24. ↵
    Gulick J, Subramaniam A, Neumann J, Robbins J. Isolation and characterization of the mouse cardiac myosin heavy chain genes. J Biol Chem. 1991;266:9180–9185.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Reddy VB, Thimmappaya B, Dhar R, Subramanian KN, Zain BS, Pan J, Ghosh PK, Celma ML, Weissman SM. The genome of simian virus 40. Science. 1978;200:494–502.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Hogan B. Manipulating the mouse embryo. Plainview, NY: Cold Spring Harbor Laboratory Press; 1994.
  27. ↵
    Steinhelper ME, Cochrane KL, Field LJ. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension. 1990;16:301–307.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Soonpaa MH, Field LJ. Assessment of cardiomyocyte DNA synthesis in normal and injured adult mouse hearts. Am J Physiol. 1997;272:H220–H226.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Soonpaa MH, Koh GY, Klug MG, Field LJ. Formation of nascent intercalated disks between grafted fetal cardiomyocytes and host myocardium. Science. 1994;264:98–101.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Bullock GR, Petrusz P. Techniques in Immunocytochemistry. New York, NY: Academic Press; 1982.
  31. ↵
    Soonpaa MH, Field LJ. Assessment of cardiomyocyte DNA synthesis during hypertrophy in adult mice. Am J Physiol. 1994;266:H1439–H1445.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Kobayashi T, Nishizawa M, Hirayama Y, Kobayashi E, Hino O. cDNA structure, alternative splicing and exon-intron organization of the predisposing tuberous sclerosis (Tsc2) gene of the Eker rat model. Nucleic Acids Res. 1995;23:2608–2613.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Maheshwar MM, Sandford R, Nellist M, Cheadle JP, Sgotto B, Vaudin M, Sampson JR. Comparative analysis and genomic structure of the tuberous sclerosis 2 (TSC2) gene in human and pufferfish. Hum Mol Genet. 1996;5:131–137.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Ito N, Rubin GM. gigas, a Drosophila homolog of tuberous sclerosis gene product-2, regulates the cell cycle. Cell. 1999;96:529–539.
    OpenUrlCrossRefPubMed
  35. ↵
    Fujita K, Ohyama H, Yamada T. Quantitative comparison of in situ methods for detecting apoptosis induced by x-ray irradiation in mouse thymus. Histochem J. 1997;29:823–830.
    OpenUrlCrossRefPubMed
  36. ↵
    Soucek T, Yeung RS, Hengstschlager M. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc Natl Acad Sci U S A. 1998;95:15653–15658.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Soucek T, Pusch O, Wienecke R, DeClue JE, Hengstschlager M. Role of the tuberous sclerosis gene-2 product in cell cycle control: loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase. J Biol Chem. 1997;272:29301–29308.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Zhang H, Yamamoto T, Nanba E, Kitamura Y, Terada T, Akaboshi S, Yuasa I, Ohtani K, Nakamoto S, Takeshita K, Ohno K. Novel TSC2 mutation in a patient with pulmonary tuberous sclerosis: lack of loss of heterozygosity in a lung cyst. Am J Med Genet. 1999;82:368–370.
    OpenUrlCrossRefPubMed
  39. ↵
    Soonpaa MH, Field LJ. Survey of studies examining mammalian cardiomyocyte DNA synthesis. Circ Res. 1998;83:15–26.
    OpenUrlFREE Full Text
  40. ↵
    Anversa P, Kajstura J. Ventricular myocytes are not terminally differentiated in the adult mammalian heart. Circ Res. 1998;83:1–14.
    OpenUrlFREE Full Text
  41. ↵
    Sadoshima J, Aoki H, Izumo S. Angiotensin II and serum differentially regulate expression of cyclins, activity of cyclin-dependent kinases, and phosphorylation of retinoblastoma gene product in neonatal cardiac myocytes. Circ Res. 1997;80:228–241.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol. 1997;59:551–571.
    OpenUrlCrossRefPubMed
  43. ↵
    Hefti MA, Harder BA, Eppenberger HM, Schaub MC. Signaling pathways in cardiac myocyte hypertrophy. J Mol Cell Cardiol. 1997;29:2873–2892.
    OpenUrlCrossRefPubMed
  44. ↵
    Koh KN, Kang MJ, Frith-Terhune A, Park SK, Kim I, Lee CO, Koh GY. Persistent and heterogenous expression of the cyclin-dependent kinase inhibitor, p27KIP1, in rat hearts during development. J Mol Cell Cardiol. 1998;30:463–474.
    OpenUrlCrossRefPubMed
  45. ↵
    Li JM, Poolman RA, Brooks G. Role of G1 phase cyclins and cyclin-dependent kinases during cardiomyocyte hypertrophic growth in rats. Am J Physiol. 1998;275:H814–H822.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell. 1996;85:733–744.
    OpenUrlCrossRefPubMed
  47. ↵
    Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell. 1996;85:721–732.
    OpenUrlCrossRefPubMed
  48. ↵
    Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 1996;85:707–720.
    OpenUrlCrossRefPubMed
  49. ↵
    Poolman RA, Li JM, Durand B, Brooks G. Altered expression of cell cycle proteins and prolonged duration of cardiac myocyte hyperplasia in p27KIP1 knockout mice. Circ Res. 1999;85:117–127.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    Soonpaa MH, Koh GY, Pajak L, Jing S, Wang H, Franklin MT, Kim KK, Field LJ. Cyclin D1 overexpression promotes cardiomyocyte DNA synthesis and multinucleation in transgenic mice. J Clin Invest. 1997;99:2644–2654.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation Research
May 26, 2000, Volume 86, Issue 10
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics

Article Tools

  • Print
  • Citation Tools
    Enhanced Cardiomyocyte DNA Synthesis During Myocardial Hypertrophy in Mice Expressing a Modified TSC2 Transgene
    Kishore B. S. Pasumarthi, Hidehiro Nakajima, Hisako O. Nakajima, Shaoliang Jing and Loren J. Field
    Circulation Research. 2000;86:1069-1077, originally published May 26, 2000
    https://doi.org/10.1161/01.RES.86.10.1069

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation Research.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Enhanced Cardiomyocyte DNA Synthesis During Myocardial Hypertrophy in Mice Expressing a Modified TSC2 Transgene
    (Your Name) has sent you a message from Circulation Research
    (Your Name) thought you would like to see the Circulation Research web site.
  • Share on Social Media
    Enhanced Cardiomyocyte DNA Synthesis During Myocardial Hypertrophy in Mice Expressing a Modified TSC2 Transgene
    Kishore B. S. Pasumarthi, Hidehiro Nakajima, Hisako O. Nakajima, Shaoliang Jing and Loren J. Field
    Circulation Research. 2000;86:1069-1077, originally published May 26, 2000
    https://doi.org/10.1161/01.RES.86.10.1069
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Basic, Translational, and Clinical Research
    • Myocardial Biology
    • Myocardial Regeneration
    • Cell Signaling/Signal Transduction

Circulation Research

  • About Circulation Research
  • Editorial Board
  • Instructions for Authors
  • Abstract Supplements
  • AHA Statements and Guidelines
  • Permissions
  • Reprints
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
3355 Keswick Rd
Main Bldg 103
Baltimore, MD 21211
CircRes@circresearch.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured